Rodman & Renshaw initiated coverage of Cardiol Therapeutics (CRDL) with a Buy rating and $7 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks